Top 9 Nanobiotechnology Companies are Driving Innovation at Nanoscale in 2025

At a scale smaller than a cell, what happens when biology and engineering come together? You get nanobiotechnology, an area in which science begins to redesign life instead. Nanobiotechnology is not only improving healthcare but also redefining what precision in medicine actually means, from ultra-sensitive diagnostics to tailored drug delivery. The market is becoming a potent convergence point, combining biology, chemistry, physics, and engineering into a single transformational force, as industries seek more intelligent, quicker, and effective solutions.

The Science Behind the Scale

At the nanoscale, which is usually between 1 and 100 nanometers, nanobiotechnology works with materials that have special chemical, biological, and physical characteristics. Nanoparticles can directly interact with biomolecules including proteins, DNA, and cells.

These interactions facilitate innovation such as:

• Nanosensors that can identify illnesses early on.
• Targeted medication delivery systems that reduce adverse effects.
• Application of regenerative medicine for tissue repair.
• Cutting-edge imaging methods with improved precision and resolution.

Fortune Business Insights estimates the market for nanobiotechnology to grow from USD 76.17 billion in 2025 to USD 403.53 billion by 2034, with a significant CAGR of 21.06% over the forecast period.

Fortune Business Insights Discloses its Top 9 Nanobiotechnology Companies

1. Cytiva

Based in Marlborough, Massachusetts, U.S., Cytiva was rebranded in 2020 after being a part of GE Healthcare Life Sciences. The company focuses on bioprocessing, cell and gene therapy, and research equipment. Under the Cytiva brand, its Sefia™ cell processing systems, and KTATM chromatography are utilized in the creation of viral vectors, LNP drug delivery, and mRNA vaccines. In order to speed up mRNA and exosome-based treatments, the company collaborates with developers. These partnerships lay efforts to improve the purification procedures for cutting-edge nanomedicines.

2. Merck KGaA

In 1668, Merck KGaA was established in Darmstadt, Germany. The company focuses on life science, healthcare, and electronics. The life science division is responsible for innovative materials, nanobiotech, and cell and gene therapy. Lipid nanoparticles mRNA reagents, quantum dots, and filtration under the Merck, Millipore®, and SAFC® brands are all part of its portfolio in the pharmaceutical, biotech, and academic industries. In an effort to increase specificity for therapeutic payloads, Merck and Biocytogen partnered in September 2025 to create antibody-conjugated lipid nanoparticles for targeted nucleic acid delivery.

3. Waters Corporation

Based in Massachusetts, U.S., Waters Corporation was established in 1958. The company focuses on analytical tools, software, and consumables. Its ACQUITY™ UPLC, Xevo™ TQ Absolute MS, BioAccord™ LC-MS, and OligoWorks™ are used for LNP characterization, oligonucleotide bioanalysis, and mRNA vaccine quality control. In order to enhance the quick characterization of big molecules, including nanoparticles, Waters unveiled an extended-range Multi-Angle Light Scattering (MALS) detector for UHPLC/UPLC systems in April 2026.

4. IZON Science LTD

Based in Christchurch, New Zealand, Izon Science Ltd. was established in 2005. Its qEV and Exoid platforms are utilized in more than 1,000 labs globally, with a focus on nanoparticle analysis and isolation. Research involving extracellular vesicles, LNP, AAV, and nanomedicine uses its Extoid Tunable Resistive Pulse Sensing, qEV Size Exclusion Columns, and qEV Isolation platform. The firm is currently focusing on improving the speed, purity, and scalability of EV analysis.

5. Unchained Labs.

Located in California, U.S., Unchained Labs was established in 2015. With more than 10 product lines utilized by more than 500 biopharmaceutical companies globally, the focus is on technologies that “unclog” the development of biologics and gene therapies. Unchained Labs examines the size and stability of nanoparticles. Its Stunner, Leprechaun, Big Tuna, and Honeybun systems are utilized for mRNA measurement, AAV tittering, and LNP formation. In July 2025, it added “Add Fluorescence” functionality to their Stunner platform, offering thorough LNP characterization in a single, high-throughput step, including payload measurement, encapsulation efficiency, and size.

6. Malvern Panalytical Ltd

Based in Malvern, U.K., Malvern Panalytical Ltd. was established in 2017 by combining Panalytical and Malvern Instruments. With equipment in more than 10,000 labs in the pharmaceutical, biotech, and academic sectors, the focus is on materials and biophysical characterization. LNP, AAV, EV, and protein aggregation analysis employ its Zetasizer, NanoSight, Mastersizer, and Omnisec equipment under the Malvern brand. With a focus on the optimization of nanobubbles and intricate drug delivery systems, the new NanoSight Pro uses sophisticated Nanoparticle Tracking Analysis (NTA) to quantify particle size and concentration with high resolution.

7. Oxford Nanopore Technologies plc.

Oxford Nanopore Technologies plc. situated in Oxford Science Park, U.K., was established in 2005. The company focuses on nanopore sensing for DNA and RNA. Under the company’s brand, its MinION, GridION, and PromethION devices as well as direct RNA sequencing kits are utilized for viral vector sequencing, sgRNA impurity analysis, mRNA-LNP QC, and AAV characterization.

8. nanoComposix

Based in San Diego, U.S., nanoComposix was established in 2004. With more than 2,000 materials and ISO 13485+ FDA- registered cGMP manufacturing, the focus is on custom and catalog nanoparticles. The firm manufactures the particles. Lateral Flow tests, LNP excipients, and nanomedicine research and development employ its gold, silica, silver PLGA, and magnetic nanoparticles together with BioReady™ LNP reagents under its brand.

9. Nanospectra Biosciences, Inc.

Nanospectra Biosciences, Inc. was established in Houston, Texas, U.S., in 2002. AuroLase® therapy, which combines silica-gold nanoshells with a near-infrared laser for targeted tumor ablation, is the company’s main focus. Under the AuroLase® brand in prostate cancer trials and pipeline indication, its AuroShell®gold-silica nanoshells are injected intravenously, collected in tumors via EPR, and then activated by an 808 nm laser.

Nanobiotechnology: Redefining the Limits of Biology

Our understanding of and interactions with life itself have fundamentally changed as a result of nanibiotechnology. It provides previously unheard-of levels of accuracy, productivity, and creativity in a variety of industries by functioning as the molecular level. The industry is gradually moving from experimental promise to commercial reality as research continues to develop into practical applications. It is positioned as a major force in the future of healthcare thanks to its capacity to provide focused, effective, and highly customized solutions.